Figure 9.

Bemarituzumab demonstrates biphasic disposition in rats and cynomolgus monkeys following a single IV injection. a: Bemarituzumab plasma concentration in rats following a single IV injection at 1.5 mg/kg (●; n = 4), 10 mg/kg (■; n = 4), or 30 mg/kg (▲; n = 3). Based on the concentration profiles, 2 animals (1 in the 1.5 mg/kg group and 1 in the 10 mg/kg group) were suspected of inadvertent subcutaneous dosing. b: Plasma concentrations of bemarituzumab and FPA144-F in cynomolgus monkeys following a single IV injection of bemarituzumab 10 mg/kg (–■̶; n = 1), bemarituzumab 13.5 mg/kg (–●̶; n = 1), or FPA144-F 10 mg/kg (-●-, -■-; n = 2). Each symbol represents a concentration time point for an individual animal. The lower limit of quantification (–) was 50 ng/mL